Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with chronic myeloid leukemia (CML) at any stage of the disease (early/chronic stage, accelerated stage, or advanced/blast stage)
- You have previously been treated with at least one approved medication for CML (such as imatinib, dasatinib, or nilotinib)
- Your CML treatment was not part of a clinical trial at MD Anderson Cancer Center (MDACC)
- You have had at least one clinic visit at MD Anderson Cancer Center, regardless of your full treatment history
Who may not be able to join:
- There are no listed exclusion criteria for this trial (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Koji Sasaki, M.D., M.D. Anderson Cancer Center
Phone: (713) 745-2882
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
CML Patient Response to standard dose imatinib treated outside clinical trial setting
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.